Global Health Financing: Diversifying Beyond Declining Aid Budgets

Global health financing faces a critical juncture, as traditional aid budgets shrink and a more complex funding landscape emerges. A recent analysis by Bertrand Badré and Johanna Benesty highlights a growing structural vulnerability in the system, one historically reliant on a narrow base of official development assistance (ODA). The shift demands a more resilient model combining grants, concessional loans, and private capital to maintain progress in global health outcomes.

The Shrinking Aid Pool

For decades, official development assistance grants have formed the bedrock of health-related aid to developing economies, accounting for 75-95% of funding as of 2023. This heavy reliance on public budgets from a handful of donor countries has proven precarious. Recent trends show a significant downturn. Total ODA fell by more than $15 billion in 2024, and projections indicate a further decline of 9-17% in 2025, potentially jeopardizing $40-55 billion in development assistance. Bilateral ODA for health is shrinking even faster, with a projected drop of 19-33% between 2023 and 2025, pushing funding levels below pre-pandemic levels.

The impact is already being felt across the global health landscape. The Joint United Nations Programme on HIV/AIDS (UNAIDS) anticipates halving its staff and scaling back operations from 75 to 36 countries following a substantial reduction in US funding. The World Health Organization (WHO) has also proposed a 14% cut to its core budget for 2026-27. These cuts will disproportionately affect the least developed countries (LDCs), where bilateral ODA is projected to fall by 13-25% in 2025, and even steeper declines – 16-28% – are expected in Sub-Saharan Africa. In the ten countries with the highest levels of extreme poverty, the top five donors provide 85% of ODA, with the United States and the World Bank being dominant players in eight of them.

Beyond Traditional Aid: A Shifting Landscape

The decline in ODA isn’t simply a cyclical downturn. it reflects a structural shift. Between 2011 and 2024, health-related development assistance fell by roughly 24% as a share of global GDP, despite a temporary surge during the COVID-19 pandemic. The rationale for health aid has also evolved, moving away from solidarity and human development towards economic interests, national security, and pandemic preparedness.

Simultaneously, the development finance landscape is becoming increasingly crowded. The BRICS+ nations – China, Russia, and India, among others – are collectively providing over $100 billion in development funding annually since 2022, with China accounting for approximately 80% of that total. These newer providers often favor bilateral, project-based approaches, loans over grants, and infrastructure-heavy investments, concentrating resources in strategically important regions. This contrasts with the more geographically dispersed approach of traditional donors.

Private and impact investors are also playing a growing role, particularly in Africa and Asia. Health-care-focused private equity and impact funds are providing patient capital and innovative financing structures, creating opportunities for investments that deliver both financial returns and measurable health benefits. However, not all health projects are suitable for this type of capital. An analysis of health-security action plans in Côte d’Ivoire and Uganda suggests that only 25-30% of budgeted projects combine direct health impact with predictable cash flows and clear revenue models. These typically involve infrastructure investments like oncology centers that can generate service revenues.

Unlocking Private Capital: The Investment Lens

The Boston Consulting Group estimates that projects representing roughly 20% of national health spending, and potentially up to 30% of global portfolios, could attract return-seeking investors. To unlock this potential, a shift in perspective is needed. Health outcomes must turn into “legible” to investors, meaning they need to be framed in quantitative terms that link investments to the Sustainable Development Goals (SDGs) and portfolio-level performance. Systems like the SDG Blue rating system, developed by Blue Like an Orange Sustainable Capital, assign scores to investments based on their contribution to specific SDGs, providing a standardized metric for impact assessment.

The Need for Project Categorization

Badré and Benesty argue for a fundamental reset in how global health is financed. National and global portfolios should be broken down into distinct project types, each matched to the most appropriate form of financing based on its risk profile. Government grants and concessional loans should continue to support low-income countries, vulnerable populations, and essential public goods. Infrastructure and service-based initiatives with clear revenue models can attract private and impact capital. Blended finance arrangements, combining public, philanthropic, and private resources, can bridge the gap between these approaches.

Implications for Multilateral Institutions

The changing funding landscape presents significant challenges for multilateral institutions like UNAIDS and the WHO. Reduced ODA forces these organizations to prioritize programs, streamline operations, and seek alternative funding sources. The reliance on a smaller number of donor countries also increases their vulnerability to political shifts and budgetary constraints in those countries. This necessitates a more diversified funding base and a greater emphasis on demonstrating impact and value for money.

Navigating the Future of Global Health Finance

Successfully navigating this transition requires effective collaboration between governments, multilateral institutions, and development partners. Structuring financing mechanisms, sorting projects by risk, and engaging investors are crucial steps. Recognizing that impact and financial returns can be mutually reinforcing is key to building a more resilient and diversified financing model that protects and builds upon past gains, even as public budgets face increasing pressure. The current situation demands a proactive and innovative approach to ensure continued progress in global health.

Looking Ahead: The coming months will be critical for observing how multilateral institutions adapt to the funding cuts and how effectively they can attract private capital. Monitoring the implementation of blended finance initiatives and the adoption of standardized impact measurement frameworks, like SDG Blue, will be key indicators of progress. Further analysis of the evolving role of BRICS+ nations in global health financing will also be essential to understanding the long-term implications of this shifting landscape.